未登录

N

Nathan G. Dolloff

department of pharmacology and immunology

H指数:23

被引数:1,886

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia

一种基于超抗原的MHC II类分子靶向癌症免疫疗法，用于治疗急性髓系白血病

Blood Cancer Journal

IF11.6

2025-11-170

OAAI

A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17)

IF2.7

2024-12-050

OAAI

Secreted frizzled related-protein 2 is prognostic for survival in pancreatic cancer

CANCER RESEARCH

IF16.6

2024-01-160

PRE

Biotherapeutic strategies targeting the CXCR2 axis for depletion of myeloid-derived suppressor cells in pancreatic ductal adenocarcinoma

CANCER RESEARCH

IF16.6

2024-01-160

PRE

Stimulation of natural killer cells with small molecule inhibitors of CD38 for the treatment of neuroblastoma

CHEMICAL SCIENCE

IF7.4

2023-01-014

OAAI

ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors

CANCER RESEARCH

IF16.6

2020-08-1417

OAAI

Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2020-04-2247

OAAI

Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2020-01-0116

OAAI

Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors

IF5.2

2019-11-2617

OAAI

ATF3 drives synergy between protein disulfide isomerase (PDI) inhibitors and epigenetic cancer therapy

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Specifically targeting PDIA1 with indene inhibitors leads to bortezomib-potentiation in multiple myeloma

CANCER RESEARCH

IF16.6

2019-07-011

PRE

Discovery platform for inhibitors of IgH gene enhancer activity

CANCER BIOLOGY & THERAPY

IF4.6

2018-11-277

OAAI

Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma

IF13.4

2018-10-1240

OAAI

CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth

IF3.4

2014-10-3193

OAAI

The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions

IF3.4

2014-10-2872

OAAI

Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab

IF3.4

2014-10-2862

OAAI

Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer

CANCER BIOLOGY & THERAPY

IF4.6

2014-10-2739

OAAI

Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents

CANCER BIOLOGY & THERAPY

IF4.6

2014-10-2745

OAAI

Spectral imaging-based methods for quantifying autophagy and apoptosis

CANCER BIOLOGY & THERAPY

IF4.6

2014-10-2715

OAAI

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma

IF13.4

2014-07-0911

PREAI